The homophilic cell adhesion molecule PECAM-1 is a major participant in the migration of leukocytes across endothelium. We examined the ability of a chimeric soluble PECAM-1 fused to human IgG-Fc to impair leukocyte entry through the blood-brain barrier and reduce CNS autoimmunity. sPECAM-Fc impaired migration of lymphocytes across brain endothelial monolayers and diminished the severity of EAE, an experimental model of MS, when administered at the onset of symptoms. However, in mice transgenic for sPECAM-Fc, the chronically elevated levels of sPECAM-Fc hastened onset of EAE disease without significantly changing clinical score severity. Our data suggest that short-term treatment of diseases like MS with sPECAM-Fc has therapeutic potential.
Introduction
Platelet endothelial cell adhesion molecule (PECAM)-1 (CD31) is a cell adhesion molecule found on leukocytes and vascular endothelium. Homophilic interactions between PECAM-1 on both leukocyte and endothelium are necessary for the migration of leukocytes through the vasculature from blood to tissue (Muller et al., 1993) . In CNS autoimmunity, leukocytes migrate through the blood-brain barrier, a unique vascular structure, to enter the brain and spinal cord. Soluble (s) PECAM-1 has the potential to compete with and interfere with the PECAM-PECAM interactions between the brain microvascular endothelial cells and the entering leukocytes and may reduce the number of invading cells and improve clinical outcome.
Several in vitro and in vivo studies have examined the effects of PECAM-1 inhibition on cellular migration across endothelial cells or vessels. In vitro, sPECAM-1 and anti-PECAM-1 antibodies inhibit the passage of immune cells across layers of endothelial cells (Liao et al., 1995 (Liao et al., , 1997 Muller et al., 1993; Wong et al., 1999) . In vivo in several species, treatment with sPECAM-1 blocks leukocyte entry into the peritoneum in response to thioglycolate (Bogen et al., 1994; Liao et al., 1999; Schenkel et al., 2004) , lungs in response to immune complexes (Vaporciyan et al., 1993) , and muscle in response to ischemia/ reperfusion injury (Farooq et al., 2001; Gumina et al., 1996; Murohara et al., 1996) . Additionally, T cell accumulation in the cerebral spinal fluid in response to infused antigen is impaired
